These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33392964)

  • 1. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of leukemia-associated SHP2
    Sun X; Ren Y; Gunawan S; Teng P; Chen Z; Lawrence HR; Cai J; Lawrence NJ; Wu J
    Leukemia; 2018 May; 32(5):1246-1249. PubMed ID: 29568093
    [No Abstract]   [Full Text] [Related]  

  • 3. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
    LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
    Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
    Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
    Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
    Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
    Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
    Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C
    J Biol Chem; 2021; 296():100538. PubMed ID: 33722610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
    Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
    J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
    Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
    Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors.
    Zhang L; Ma W; Chen Y; Chen Z; Wang F; Xu Y
    Bioorg Chem; 2024 Oct; 151():107661. PubMed ID: 39067422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
    Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
    J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of the injectable thermosensitive hydrogel loaded with SHP099 on intervertebral disc degeneration.
    Wang J; Huang L; Huang Y; Jiang Y; Zhang L; Feng G; Liu L
    Life Sci; 2021 Feb; 266():118891. PubMed ID: 33310047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.